Distinct patterns of SARS-CoV-2 BA.2.87.1 and JN.1 variants in immune evasion, antigenicity, and cell-cell fusion

mBio, Journal Year: 2024, Volume and Issue: 15(5)

Published: April 9, 2024

The rapid evolution of SARS-CoV-2 variants presents a constant challenge to the global vaccination effort. In this study, we conducted comprehensive investigation into two newly emerged variants, BA.2.87.1 and JN.1, focusing on their neutralization resistance, infectivity, antigenicity, cell-cell fusion, spike processing. Neutralizing antibody (nAb) titers were assessed in diverse cohorts, including individuals who received bivalent mRNA vaccine booster, patients infected during BA.2.86/JN.1-wave, hamsters vaccinated with XBB.1.5-monovalent vaccine. We found that shows much less nAb escape from WT-BA.4/5 JN.1-wave breakthrough infection sera compared JN.1 XBB.1.5. Interestingly, is more resistant by XBB.1.5-monovalent-vaccinated hamster than BA.2.86/JN.1 XBB.1.5, but efficiently neutralized class III monoclonal S309, which largely fails neutralize BA.2.86/JN.1. Importantly, exhibits higher levels fusion activity, furin cleavage efficiency Antigenically, closer ancestral BA.2 other recently Omicron subvariants Altogether, these results highlight immune properties as well biology new underscore importance continuous surveillance informed decision-making development effective vaccines.

Language: Английский

---

SARS-CoV-2 omicron BA.2.87.1 exhibits higher susceptibility to serum neutralization than EG.5.1 and JN.1

Emerging Microbes & Infections, Journal Year: 2024, Volume and Issue: 13(1)

Published: May 23, 2024

As SARS-CoV-2 continues to spread and mutate, tracking the viral evolutionary trajectory understanding functional consequences of its mutations remain crucial. Here, we characterized antibody evasion, ACE2 receptor engagement, infectivity highly mutated Omicron subvariant BA.2.87.1. Compared with other subvariants, including EG.5.1 current predominant JN.1, BA.2.87.1 exhibits less immune reduced comparable in Calu-3 lung cells. Intriguingly, two large deletions (Δ15-26 Δ136-146) N-terminal domain (NTD) spike protein facilitate subtly increased evasion but significantly diminish infectivity. Collectively, our data support announcement by USA CDC that public health risk posed appears be low.

Language: Английский

---

Distinct Patterns of SARS-CoV-2 BA.2.87.1 and JN.1 Variants in Immune Evasion, Antigenicity and Cell-Cell Fusion

bioRxiv (Cold Spring Harbor Laboratory), Journal Year: 2024, Volume and Issue: unknown

Published: March 11, 2024

The rapid evolution of SARS-CoV-2 variants presents a constant challenge to the global vaccination effort. In this study, we conducted comprehensive investigation into two newly emerged variants, BA.2.87.1 and JN.1, focusing on their neutralization resistance, infectivity, antigenicity, cell-cell fusion, spike processing. Neutralizing antibody (nAb) titers were assessed in diverse cohorts, including individuals who received bivalent mRNA vaccine booster, patients infected during BA.2.86/JN.1-wave, hamsters vaccinated with XBB.1.5-monovalent vaccine. We found that shows much less nAb escape from WT-BA.4/5 JN.1-wave breakthrough infection sera compared JN.1 XBB.1.5. Interestingly. is more resistant by XBB.15-monovalent-vaccinated hamster than BA.2.86/JN.1 XBB.1.5, but efficiently neutralized class III monoclonal S309, which largely fails neutralize BA.2.86/JN.1. Importantly, exhibits higher levels fusion activity, furin cleavage efficiency Antigenically, closer ancestral BA.2 other recently Omicron subvariants Altogether, these results highlight immune properties as well biology new underscore importance continuous surveillance informed decision-making development effective vaccines.

Language: Английский

---

COVID-19 Serum Drives Spike-Mediated SARS-CoV-2 Variation

Viruses, Journal Year: 2024, Volume and Issue: 16(5), P. 763 - 763

Published: May 11, 2024

Neutralizing antibodies targeting the spike (S) protein of SARS-CoV-2, elicited either by natural infection or vaccination, are crucial for protection against virus. Nonetheless, emergence viral escape mutants presents ongoing challenges contributing to breakthrough infections. To define evolution trajectory SARS-CoV-2 within immune population, we co-incubated replication-competent rVSV/SARS-CoV-2/GFP chimeric viruses with sera from COVID-19 convalescents. Our findings revealed that E484D mutation contributes increased resistant both convalescent and vaccinated sera, while L1265R/H1271Y double enhanced infectivity in 293T-hACE2 Vero cells. These suggest under selective pressure polyclonal antibodies, has potential accumulate mutations facilitate evasion greater infectivity, facilitating its adaption neutralizing antibody responses. Although identified this study currently exhibit low prevalence circulating populations, continuous meticulous surveillance remains crucial. Moreover, there is an urgent necessity develop next-generation therapeutics vaccines target diverse, less mutation-prone antigenic sites ensure more comprehensive durable SARS-CoV-2.

Language: Английский

---

A comprehensive review on DCN1 protein, inhibitors and their therapeutic applications

International Journal of Biological Macromolecules, Journal Year: 2024, Volume and Issue: 277, P. 134541 - 134541

Published: Aug. 5, 2024

Language: Английский

---

Ultrapotent IgA dimeric antibodies neutralize emerging Omicron variants

Journal of Virology, Journal Year: 2024, Volume and Issue: 99(1)

Published: Dec. 4, 2024

---